New Data Utilizing the Eeva™ Technology to be presented at the American Society for Reproductive Medicine 2013 Annual Meeting

BOSTON and MENLO PARK, Calif., Oct. 10, 2013 /PRNewswire/ -- Auxogyn, Inc., a leader in reproductive health that provides novel scientific and clinically validated solutions to in vitro fertilization (IVF) clinicians and their patients, today announced upcoming presentations of the latest research data on its Eeva™ Technology the American Society for Reproductive Medicine (ASRM) Annual Meeting.  The meeting is being held October 12-17 in Boston.

"We are pleased that our Eeva Technology and resulting clinical data will be so prominently represented at the upcoming ASRM Annual Meeting," stated Lissa Goldenstein, President and CEO of Auxogyn.  "Auxogyn remains committed to supporting the pursuit of clinical research with the goal of improving clinical care and outcomes for women undergoing IVF."

Notable data from Auxogyn at ASRM 2013 include:

• Embryos Exhibiting Abnormal First Cytokinesis Phenotypes Are Associated With Poorer Embryo Development And Lower Implantation Potential – Tuesday, October 15, 4:15-4:30 p.m. EDT (oral presentation - P-327)
  • Multisite retrospective cohort study to determine the incidence of a novel abnormal first cytokinesis phenotype evaluated during the first cytokinesis and assessed clinical relevance
    
    
• Embryo Cleavage Kinetics Under Different Oxygen Tensions Predict Embryonic Developmental Potential In The Mouse – Tuesday, October 15, 7:00-8:45 a.m. EDT (poster - P-371)
  • Laboratory research to determine ability of early cytokinesis events measured by time-lapse microscope to predict mouse blastocyst development
    
    
• Blastocyst Development Of Rhesus Macaque Embryos Produced By Intracytoplasmic Sperm Injection (ICSI) Is Dependent On Early Cytokinesis – Tuesday, October 15, 7:00-8:45 a.m. EDT (poster - P-330)
  • Prospective study to determine similarity of early developmental events in rhesus macaque embryos to human embryos and whether predictive parameters for blastocyst development could be determined with novel use of time-lapse imagery to evaluate macaque embryos
    
    
• Early Times To Cavitation Are Associated With A Reduced Prevalence Of Aneuploidy In Embryos Cultured To The Blastocyst Stage – A Prospective Blinded Morphokinetic Study – Wednesday, October 16, 7:00-8:30 a.m. EDT (poster - P-811)
  • Prospective study to evaluate relationship factors influencing embryonic reproductive competence such as early cleavage rates and aneuploidy
    
    
• Elucidating How Fragmentation And Other Blastomere Dynamics Affect Embryo Development And Clinical Outcomes – Tuesday, October 15, 12:00 PM – 12:45 PM EDT (video summary)
  • Study utilizing time-lapse imaging to understand how dynamic morphological features, such as fragmentation, impact embryonic health and clinical outcomes
    
    
• Using A Novel Time-Lapse Platform With Automated Image Analysis Can Detect Diverse Abnormal Cleavage Patterns That Are Not Recognized By Traditional Morphology And Correlate With Poor Implantation – Thursday, October 17, 7:00-8:45 a.m. EDT (poster - P-1091)
  • Retrospective cohort study assessing the clinical relevance of zygote AC (AC1) and daughter cell AC (AC2) to examine the potential of using automated time-lapse cleavage analysis to deselect AC

Please note that all abstracts are embargoed until the date and time of publication.

Auxogyn is also sponsoring a seminar covering the latest information on embryo assessment:

• Development and Application Of The First Embryo Assessment Test: Time-Lapse Enabled Technology, Clinical Validation and Generalization – Monday, October 14, 7:00-9:00 p.m. EDT (Seaport Boston World Trade Center)

Full session details and data presentation listings for the 2013 meeting can be found on the ASRM website at www.asrm.org/IFFS-ASRM2013/.

About Auxogyn 
Auxogyn is a leader in reproductive health that provides novel scientific and clinically validated solutions to IVF clinicians and their patients by translating scientific discoveries in early embryo development into clinical tools.  The Company's flagship product, the Eeva™ Test, delivers objective information regarding embryo development that IVF clinicians and patients can use to make important treatment decisions.  Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech.  For more information visit auxogyn.com and follow us on Twitter @Auxogyn.

About the Eeva™ Test 
The Eeva Test provides IVF clinicians with information about the embryo's development potential. Eeva proprietary software automatically analyzes embryo development against scientifically validated cell-division parameters conceived by researchers at Stanford University in the US.  With results from the Eeva Test, IVF teams will have morphological assessment and objective information to  aid their embryo selection decisions.  The Eeva Test was evaluated in a prospective, multi-center, 160-patient prospective multi-center trial with ~1,800 embryos.  Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting and published by Conaghan et al in Fertility and Sterility, May 2013.

The Eeva Test is currently CE Marked and available for use in the EU and authorized by Health Canada for sale in Canada.  The FDA submission is pending and Eeva is not available for sale in the United States.  For a full list of clinics in the EU offering the Eeva Test please visit www.eevaivf.com or follow us on Twitter @EevaIVF.

SOURCE Auxogyn